Selected research
Industry Research
High Purity Pharmaceutical Excipient Industry Research Report 2026
Market perspective
The global High Purity Pharmaceutical Excipient market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for High Purity Pharmaceutical Excipient is forecast to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for High Purity Pharmaceutical Excipient is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for High Purity Pharmaceutical Excipient is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of High Purity Pharmaceutical Excipient include among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global High Purity Pharmaceutical Excipient market in revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of types and applications, harmonizes vendor attribution, and presents comparable time series by company, type, application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for manufacturers, new entrants, channel partners, and investors; the report also reviews technology shifts and notable product introductions relevant to High Purity Pharmaceutical Excipient.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
High Purity Pharmaceutical Excipient Market by Company
Evonik
BASF
Syensqo
Mitsubishi
JRS Pharma
Croda Pharma
Ashland
Roquette
Seqens
High Purity Pharmaceutical Excipient Segment by Type
Natural Excipients
Semi-natural Excipients
Completely Synthetic Excipients
High Purity Pharmaceutical Excipient Segment by Application
Injectable Medications
Ocular Medications
Oral Medications
Medications Inhaled Through the Nose or Mouth
Others
High Purity Pharmaceutical Excipient Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global High Purity Pharmaceutical Excipient market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of High Purity Pharmaceutical Excipient and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of High Purity Pharmaceutical Excipient.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of High Purity Pharmaceutical Excipient manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of High Purity Pharmaceutical Excipient by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of High Purity Pharmaceutical Excipient in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Natural Excipients
- Semi-natural Excipients
- Completely Synthetic Excipients
Applications
- Injectable Medications
- Ocular Medications
- Oral Medications
- Medications Inhaled Through the Nose or Mouth
- Others
Companies covered
- Evonik
- BASF
- Syensqo
- Mitsubishi
- JRS Pharma
- Croda Pharma
- Ashland
- Roquette
- Seqens
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 High Purity Pharmaceutical Excipient by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.2.2 Natural Excipients
- 2.2.3 Semi-natural Excipients
- 2.2.4 Completely Synthetic Excipients
- 2.3 High Purity Pharmaceutical Excipient by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Injectable Medications
- 2.3.3 Ocular Medications
- 2.3.4 Oral Medications
- 2.3.5 Medications Inhaled Through the Nose or Mouth
- 2.3.6 Others
- 2.4 Global Market Growth Prospects
- 2.4.1 Global High Purity Pharmaceutical Excipient Production Value Estimates and Forecasts (2021-2032)
- 2.4.2 Global High Purity Pharmaceutical Excipient Production Capacity Estimates and Forecasts (2021-2032)
- 2.4.3 Global High Purity Pharmaceutical Excipient Production Estimates and Forecasts (2021-2032)
- 2.4.4 Global High Purity Pharmaceutical Excipient Market Average Price (2021-2032)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global High Purity Pharmaceutical Excipient Production by Manufacturers (2021-2026)
- 3.2 Global High Purity Pharmaceutical Excipient Production Value by Manufacturers (2021-2026)
- 3.3 Global High Purity Pharmaceutical Excipient Average Price by Manufacturers (2021-2026)
- 3.4 Global High Purity Pharmaceutical Excipient Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global High Purity Pharmaceutical Excipient Key Manufacturers, Manufacturing Sites & Headquarters
- 3.6 Global High Purity Pharmaceutical Excipient Manufacturers, Product Type & Application
- 3.7 Global High Purity Pharmaceutical Excipient Manufacturers Established Date
- 3.8 Global High Purity Pharmaceutical Excipient Market CR5 and HHI
- 3.9 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Evonik
- 4.1.1 Evonik High Purity Pharmaceutical Excipient Company Information
- 4.1.2 Evonik High Purity Pharmaceutical Excipient Business Overview
- 4.1.3 Evonik High Purity Pharmaceutical Excipient Production Capacity, Value and Gross Margin (2021-2026)
- 4.1.4 Evonik Product Portfolio
- 4.1.5 Evonik Recent Developments
- 4.2 BASF
- 4.2.1 BASF High Purity Pharmaceutical Excipient Company Information
- 4.2.2 BASF High Purity Pharmaceutical Excipient Business Overview
- 4.2.3 BASF High Purity Pharmaceutical Excipient Production Capacity, Value and Gross Margin (2021-2026)
- 4.2.4 BASF Product Portfolio
- 4.2.5 BASF Recent Developments
- 4.3 Syensqo
- 4.3.1 Syensqo High Purity Pharmaceutical Excipient Company Information
- 4.3.2 Syensqo High Purity Pharmaceutical Excipient Business Overview
- 4.3.3 Syensqo High Purity Pharmaceutical Excipient Production Capacity, Value and Gross Margin (2021-2026)
- 4.3.4 Syensqo Product Portfolio
- 4.3.5 Syensqo Recent Developments
- 4.4 Mitsubishi
- 4.4.1 Mitsubishi High Purity Pharmaceutical Excipient Company Information
- 4.4.2 Mitsubishi High Purity Pharmaceutical Excipient Business Overview
- 4.4.3 Mitsubishi High Purity Pharmaceutical Excipient Production Capacity, Value and Gross Margin (2021-2026)
- 4.4.4 Mitsubishi Product Portfolio
- 4.4.5 Mitsubishi Recent Developments
- 4.5 JRS Pharma
- 4.5.1 JRS Pharma High Purity Pharmaceutical Excipient Company Information
- 4.5.2 JRS Pharma High Purity Pharmaceutical Excipient Business Overview
- 4.5.3 JRS Pharma High Purity Pharmaceutical Excipient Production Capacity, Value and Gross Margin (2021-2026)
- 4.5.4 JRS Pharma Product Portfolio
- 4.5.5 JRS Pharma Recent Developments
- 4.6 Croda Pharma
- 4.6.1 Croda Pharma High Purity Pharmaceutical Excipient Company Information
- 4.6.2 Croda Pharma High Purity Pharmaceutical Excipient Business Overview
- 4.6.3 Croda Pharma High Purity Pharmaceutical Excipient Production Capacity, Value and Gross Margin (2021-2026)
- 4.6.4 Croda Pharma Product Portfolio
- 4.6.5 Croda Pharma Recent Developments
- 4.7 Ashland
- 4.7.1 Ashland High Purity Pharmaceutical Excipient Company Information
- 4.7.2 Ashland High Purity Pharmaceutical Excipient Business Overview
- 4.7.3 Ashland High Purity Pharmaceutical Excipient Production Capacity, Value and Gross Margin (2021-2026)
- 4.7.4 Ashland Product Portfolio
- 4.7.5 Ashland Recent Developments
- 4.8 Roquette
- 4.8.1 Roquette High Purity Pharmaceutical Excipient Company Information
- 4.8.2 Roquette High Purity Pharmaceutical Excipient Business Overview
- 4.8.3 Roquette High Purity Pharmaceutical Excipient Production Capacity, Value and Gross Margin (2021-2026)
- 4.8.4 Roquette Product Portfolio
- 4.8.5 Roquette Recent Developments
- 4.9 Seqens
- 4.9.1 Seqens High Purity Pharmaceutical Excipient Company Information
- 4.9.2 Seqens High Purity Pharmaceutical Excipient Business Overview
- 4.9.3 Seqens High Purity Pharmaceutical Excipient Production Capacity, Value and Gross Margin (2021-2026)
- 4.9.4 Seqens Product Portfolio
- 4.9.5 Seqens Recent Developments
5 Global High Purity Pharmaceutical Excipient Production by Region
- 5.1 Global High Purity Pharmaceutical Excipient Production Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.2 Global High Purity Pharmaceutical Excipient Production by Region: 2021-2032
- 5.2.1 Global High Purity Pharmaceutical Excipient Production by Region: 2021-2026
- 5.2.2 Global High Purity Pharmaceutical Excipient Production Forecast by Region (2027-2032)
- 5.3 Global High Purity Pharmaceutical Excipient Production Value Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.4 Global High Purity Pharmaceutical Excipient Production Value by Region: 2021-2032
- 5.4.1 Global High Purity Pharmaceutical Excipient Production Value by Region: 2021-2026
- 5.4.2 Global High Purity Pharmaceutical Excipient Production Value Forecast by Region (2027-2032)
- 5.5 Global High Purity Pharmaceutical Excipient Market Price Analysis by Region (2021-2026)
- 5.6 Global High Purity Pharmaceutical Excipient Production and Value, YOY Growth
- 5.6.1 North America High Purity Pharmaceutical Excipient Production Value Estimates and Forecasts (2021-2032)
- 5.6.2 Europe High Purity Pharmaceutical Excipient Production Value Estimates and Forecasts (2021-2032)
- 5.6.3 China High Purity Pharmaceutical Excipient Production Value Estimates and Forecasts (2021-2032)
- 5.6.4 Japan High Purity Pharmaceutical Excipient Production Value Estimates and Forecasts (2021-2032)
6 Global High Purity Pharmaceutical Excipient Consumption by Region
- 6.1 Global High Purity Pharmaceutical Excipient Consumption Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 6.2 Global High Purity Pharmaceutical Excipient Consumption by Region (2021-2032)
- 6.2.1 Global High Purity Pharmaceutical Excipient Consumption by Region: 2021-2026
- 6.2.2 Global High Purity Pharmaceutical Excipient Forecasted Consumption by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America High Purity Pharmaceutical Excipient Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America High Purity Pharmaceutical Excipient Consumption by Country (2021-2032)
- 6.3.3 United States
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe High Purity Pharmaceutical Excipient Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe High Purity Pharmaceutical Excipient Consumption by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Russia
- 6.4.8 Spain
- 6.4.9 Netherlands
- 6.4.10 Switzerland
- 6.4.11 Sweden
- 6.4.12 Poland
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific High Purity Pharmaceutical Excipient Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific High Purity Pharmaceutical Excipient Consumption by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 India
- 6.5.7 Australia
- 6.5.8 Taiwan
- 6.5.9 Southeast Asia
- 6.6 South America, Middle East & Africa
- 6.6.1 South America, Middle East & Africa High Purity Pharmaceutical Excipient Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East & Africa High Purity Pharmaceutical Excipient Consumption by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 Argentina
- 6.6.5 Chile
- 6.6.6 Turkey
- 6.6.7 GCC Countries
7 Segment by Type
- 7.1 Global High Purity Pharmaceutical Excipient Production by Type (2021-2032)
- 7.1.1 Global High Purity Pharmaceutical Excipient Production by Type (2021-2032) & (Tons)
- 7.1.2 Global High Purity Pharmaceutical Excipient Production Market Share by Type (2021-2032)
- 7.2 Global High Purity Pharmaceutical Excipient Production Value by Type (2021-2032)
- 7.2.1 Global High Purity Pharmaceutical Excipient Production Value by Type (2021-2032) & (US$ Million)
- 7.2.2 Global High Purity Pharmaceutical Excipient Production Value Market Share by Type (2021-2032)
- 7.3 Global High Purity Pharmaceutical Excipient Price by Type (2021-2032)
8 Segment by Application
- 8.1 Global High Purity Pharmaceutical Excipient Production by Application (2021-2032)
- 8.1.1 Global High Purity Pharmaceutical Excipient Production by Application (2021-2032) & (Tons)
- 8.1.2 Global High Purity Pharmaceutical Excipient Production Market Share by Application (2021-2032)
- 8.2 Global High Purity Pharmaceutical Excipient Production Value by Application (2021-2032)
- 8.2.1 Global High Purity Pharmaceutical Excipient Production Value by Application (2021-2032) & (US$ Million)
- 8.2.2 Global High Purity Pharmaceutical Excipient Production Value Market Share by Application (2021-2032)
- 8.3 Global High Purity Pharmaceutical Excipient Price by Application (2021-2032)
9 Value Chain and Sales Channels Analysis of the Market
- 9.1 High Purity Pharmaceutical Excipient Value Chain Analysis
- 9.1.1 High Purity Pharmaceutical Excipient Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 High Purity Pharmaceutical Excipient Production Mode & Process
- 9.2 High Purity Pharmaceutical Excipient Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 High Purity Pharmaceutical Excipient Distributors
- 9.2.3 High Purity Pharmaceutical Excipient Customers
10 Global High Purity Pharmaceutical Excipient Analyzing Market Dynamics
- 10.1 High Purity Pharmaceutical Excipient Industry Trends
- 10.2 High Purity Pharmaceutical Excipient Industry Drivers
- 10.3 High Purity Pharmaceutical Excipient Industry Opportunities and Challenges
- 10.4 High Purity Pharmaceutical Excipient Industry Restraints
11 Report Conclusion
12 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst